Peter Bach
Showing 1–2 of 2 transcripts.
- Milken Institute1h 5m
Can We Afford to Cure Disease?
Caroline Pearson, Gregg Alton, Peter Bach, Anthony Barrueta, Roy Beveridge, Tony Beretta, Pablo Legoreto
A 2015 panel discussion highlighted a five-fold surge in media mentions of prescription drug prices driven by high-cost therapies for hepatitis C and cancer, while analyzing the structural inefficiencies of the current U.S. market. Experts including Dr. Peter Bock and representatives from Humana and Gilead debated the necessity of value-based frameworks and potential policy interventions to address disparities where inflation-adjusted treatment costs rose from $50,000 to $250,000 per life-year gained. The consensus pointed toward a future shift toward outcomes-based payment models to balance pharmaceutical innovation with the financial sustainability of a healthcare system consuming 18% of U.S. GDP.
- Milken Institute1h 1m
Health Care Delivery in the 21st Century
Sue Siegel, Annie Lamine, Larry Jamison, Jared Bernstein, Peter Bach, Carolyn Gallagher, Rachel Brathen, Eric Schmidt, David Levinson, David Freeman, Jr., Jared Dillian, Jr., John Keegan, David Kelley, Sue Killey, John McCurry, Jr., John McWhorter
A 2013 industry panel analyzed the intersection of $2 billion in digital health investment, escalating pharmaceutical pricing, and systemic inefficiencies driving healthcare to consume 18% of the U.S. GDP. Key stakeholders discussed how venture capital prioritizes waste reduction over profit while hospital systems increasingly acquire physicians to manage EHR costs and leverage drug discount programs. The discussion concluded by highlighting pilot initiatives like Cincinnati's Healthy Cities, which achieved $200 million in annual savings through care coordination, while projecting a future shift toward outcome-based value models.